Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -17.40% is 87% above its 5-year average of -136.35%, near the high end of its 5-year range (-968.42%–-17.40%).
As of the fiscal period ended Tuesday, June 30, 2026. 81.16% above its 12-month average of -92.35%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -17.40%.
RETURN ON EQUITY (ROE)
-17.40%
RETURN ON EQUITY (ROE) AVG TTM
-92.35%
RETURN ON EQUITY (ROE) AVG 3Y
-179.03%
RETURN ON EQUITY (ROE) AVG 5Y
-136.35%
RETURN ON EQUITY (ROE) AVG 10Y
-95.11%
RETURN ON EQUITY (ROE) AVG 15Y
-98.09%
RETURN ON EQUITY (ROE) AVG 20Y
-74.70%
CURRENT VS TTM AVG
+81.16%
CURRENT VS 3Y AVG
+90.28%
CURRENT VS 5Y AVG
+87.24%
CURRENT VS 10Y AVG
+81.71%
CURRENT VS 15Y AVG
+82.26%
CURRENT VS 20Y AVG
+76.71%
SECTOR MEDIAN · HEALTHCARE
-40.30%
median of 668 covered companies
CURRENT VS SECTOR MEDIAN
+56.83%
vs the sector median at left
Nektar Therapeutics
Market Cap
$1.15B
Return on Equity (ROE)
-17.40%
TTM Avg
-92.35%
3Y Avg
-179.03%
5Y Avg
-136.35%
Market Cap
$1.15B
Return on Equity (ROE)
2.51%
TTM Avg
3.60%
3Y Avg
0.50%
5Y Avg
-7.05%
Market Cap
$1.17B
Return on Equity (ROE)
-50.93%
TTM Avg
-117.72%
3Y Avg
-113.46%
5Y Avg
-86.51%
Market Cap
$1.13B
Return on Equity (ROE)
N/A
TTM Avg
35.70%
3Y Avg
35.70%
5Y Avg
35.70%
Market Cap
$1.13B
Return on Equity (ROE)
10.23%
TTM Avg
17.11%
3Y Avg
18.25%
5Y Avg
14.55%
Market Cap
$1.13B
Return on Equity (ROE)
-244.91%
TTM Avg
-17.45%
3Y Avg
-30.16%
5Y Avg
-48.76%
Market Cap
$1.13B
Return on Equity (ROE)
-6.16%
TTM Avg
-10.85%
3Y Avg
-14.08%
5Y Avg
-9.38%
Market Cap
$1.10B
Return on Equity (ROE)
1.05%
TTM Avg
-23.37%
3Y Avg
-7.64%
5Y Avg
-0.10%
Market Cap
$1.10B
Return on Equity (ROE)
-281.14%
TTM Avg
-124.20%
3Y Avg
-84.35%
5Y Avg
-63.72%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nektar Therapeutics (NKTR) | $1.15B | -17.40% | -92.35% | -179.03% | -136.35% |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.15B | 2.51% | 3.60% | 0.50% | -7.05% |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.17B | -50.93% | -117.72% | -113.46% | -86.51% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.13B | N/A | 35.70% | 35.70% | 35.70% |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.13B | 10.23% | 17.11% | 18.25% | 14.55% |
| Harrow Health, Inc. (HROW)vs › | $1.13B | -244.91% | -17.45% | -30.16% | -48.76% |
| OPKO Health, Inc. (OPK)vs › | $1.13B | -6.16% | -10.85% | -14.08% | -9.38% |
| STAAR Surgical Company (STAA)vs › | $1.10B | 1.05% | -23.37% | -7.64% | -0.10% |
| Replimune Group, Inc. (REPL)vs › | $1.10B | -281.14% | -124.20% | -84.35% | -63.72% |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.09B | -39.54% | -24.09% | 36.77% | 36.77% |
ROE
-17.4%
ROA
-14.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -17.40% |
| 2026-03-31 | -27.44% |
| 2025-12-31 | -182.65% |
| 2025-09-30 | -141.90% |
| 2025-03-31 | -968.42% |
| 2024-12-31 | -195.86% |
| 2024-09-30 | -344.29% |
| 2024-06-30 | -222.22% |
| 2024-03-31 | -138.78% |
| 2023-12-31 | -210.75% |
| 2023-09-30 | -184.27% |
| 2023-06-30 | -155.81% |
| 2023-03-31 | -172.22% |
| 2022-12-31 | -100.43% |
| 2022-09-30 | -110.17% |
| 2022-06-30 | -114.40% |
| 2022-03-31 | -80.81% |
| 2021-12-31 | -77.09% |
| 2021-09-30 | -61.81% |
| 2021-06-30 | -52.41% |
| 2021-03-31 | -43.11% |
| 2020-12-31 | -41.26% |
| 2020-09-30 | -37.52% |
| 2020-06-30 | -34.20% |
| 2020-03-31 | -35.45% |
| 2019-12-31 | -31.26% |
| 2019-09-30 | -28.58% |
| 2019-06-30 | -27.15% |
| 2019-03-31 | 40.32% |
| 2018-12-31 | 39.67% |
| 2018-09-30 | 41.66% |
| 2018-06-30 | 48.52% |
| 2018-03-31 | -220.68% |
| 2017-12-31 | -110.09% |
| 2017-09-30 | -124.84% |
| 2017-03-31 | -442.23% |
| 2016-12-31 | -174.21% |
| 2015-09-30 | -186.22% |
| 2015-06-30 | 17.34% |
| 2015-03-31 | 33.77% |
| 2014-12-31 | -148.40% |
| 2014-09-30 | -118.37% |
| 2012-12-31 | -365.51% |
| 2012-09-30 | -164.08% |
| 2012-06-30 | -103.52% |
| 2012-03-31 | -85.57% |
| 2011-12-31 | -67.73% |
| 2011-09-30 | -51.59% |
| 2011-06-30 | -41.27% |
| 2011-03-31 | -24.12% |
| 2010-12-31 | -41.85% |
| 2010-09-30 | -21.54% |
| 2010-06-30 | -41.35% |
| 2010-03-31 | -73.35% |
| 2009-12-31 | -100.15% |
| 2009-09-30 | -17.02% |
| 2009-06-30 | -18.48% |
| 2009-03-31 | -15.97% |
| 2008-12-31 | -18.06% |
| 2008-09-30 | -66.35% |
| 2008-06-30 | -37.34% |
| 2008-03-31 | -27.19% |
| 2007-12-31 | -15.28% |
| 2007-09-30 | -64.75% |
| 2007-06-30 | -59.17% |
| 2007-03-31 | -69.78% |
| 2006-12-31 | -68.16% |
| 2006-09-30 | -89.06% |
| 2006-06-30 | -86.08% |
| 2006-03-31 | -62.72% |
| 2005-12-31 | -56.64% |
| 2005-09-30 | -22.15% |
| 2005-06-30 | -22.03% |
| 2005-03-31 | -19.83% |
| 2004-12-31 | -21.80% |
| 2004-09-30 | -16.48% |
| 2004-06-30 | -15.25% |
| 2004-03-31 | -13.06% |
| 2003-12-31 | -28.43% |
| 2003-09-30 | -51.24% |
| 2003-06-30 | -51.86% |
